Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial

Canadian Journal of Cardiology

Volumn 33, Issue 8, 2017, Pages 1027-1035

  Bosch, Jackie ^a,b   Eikelboom, John W ^a   Connolly, Stuart J ^a   Bruns, Nancy Cook ^c   Lanius, Vivian ^c   Yuan, Fei ^a   Misselwitz, Frank ^c   Chen, Edmond ^c   Diaz, Rafael ^d   Alings, Marco ^e   Lonn, Eva M ^a   Widimsky, Petr ^f   Hori, Masatsugu ^g   Avezum, Alvaro ^h   Piegas, Leopoldo S ⁱ   Bhatt, Deepak L ^j   Branch, Kelley R H ^k   Probstfield, Jeffrey L ^l   Liang, Yan ^m   Liu, Lisheng ^m   Zhu, Jun ^m   Maggioni, Aldo P ⁿ   Lopez Jaramillo, Patricio ^o   O'Donnell, Martin ^p   Fox, Keith A A ^q   Kakkar, Ajay ^r   Parkhomenko, Alexander N ^s   Ertl, Georg ^t   Störk, Stefan ^t   Keltai, Katalin ^u   Keltai, Matyas ^u   Ryden, Lars ^v   Dagenais, Gilles R ^w   Pogosova, Nana ^x   Dans, Antonio L ^y   Lanas, Fernando ^z   Commerford, Patrick J ^aa   Torp Pedersen, Christian ^ab   Guzik, Tomasz J ^ac,ad   Verhamme, Peter B ^ae   Vinereanu, Dragos ^af   Kim, Jae Hyung ^ag   Ha, Jong Won ^ah   Tonkin, Andrew M ^ai   Varigos, John D ^ai   Lewis, Basil S ^aj   Felix, Camilo ^ak   Yusoff, Khalid ^al   Steg, Philippe Gabriel ^am   Aboyans, Victor ^an   Metsarinne, Kaj P ^ao   Anand, Sonia S ^a   Hart, Robert G ^a   Lamy, Andre ^a   Moayyedi, Paul ^a   Leong, Darryl P ^a   Sharma, Mukul ^a   Yusuf, Salim ^a   more..

^a HAMILTON HEALTH SCIENCES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c BAYER AG   (Germany)

^d Estudios Clínicos Latino América and Instituto Cardiovascular de Rosario ^*  (Argentina)

^e Amphia Ziekenhuis and Werkgroep Cardiologische Centra Nederland (WCN)   (Netherlands)

^f CHARLES UNIVERSITY   (Czech Republic)

^g OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^h INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

ⁱ UNIVERSITY OF SÃO PAULO   (Brazil)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^l UNIVERSITY OF WASHINGTON   (United States)

^m FUWAI HOSPITAL   (China)

ⁿ ANMCO RESEARCH CENTER   (Italy)

^o Fund Cardiovasc Oriente Colombiano   (Colombia)

^p NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^q UNIVERSITY OF EDINBURGH   (United Kingdom)

^r UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^s Ukranian Strazhesko Institute of Cardiology   (Ukraine)

^t UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^u SEMMELWEIS UNIVERSITY   (Hungary)

^v KAROLINSKA INSTITUTE   (Sweden)

^w LAVAL UNIVERSITY   (Canada)

^x NATIONAL MEDICAL RESEARCH CENTER FOR THERAPY AND PREVENTIVE MEDICINE   (Russian Federation)

^y UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^z UNIVERSIDAD DE LA FRONTERA   (Chile)

^aa UNIVERSITY OF CAPE TOWN   (South Africa)

^ab AALBORG UNIVERSITY   (Denmark)

^ac JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^ad UNIVERSITY OF GLASGOW   (United Kingdom)

^ae UNIVERSITY OF LEUVEN   (Belgium)

^af CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^ag The Catholic University of Korea   (South Korea)

^ah Yonsei University College of Medicine   (South Korea)

^ai MONASH UNIVERSITY   (Australia)

^aj Lady Davis Carmel Medical Centre   (Israel)

^ak School of Engineering Sciences and Industry   (Ecuador)

^al UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^am UNIVERSITÉ PARIS DESCARTES   (France)

^an DUPUYTREN UNIVERSITY HOSPITAL   (France)

^ao TURKU UNIVERSITY HOSPITAL   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PANTOPRAZOLE; PLACEBO; RIVAROXABAN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; OUTCOME ASSESSMENT; PATIENT MONITORING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); CARDIOVASCULAR DISEASES; FIBRINOLYTIC THERAPY; PRACTICE GUIDELINE; PROCEDURES; STANDARDS;

ANTICOAGULANTS; CARDIOVASCULAR DISEASES; HUMANS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOLYTIC THERAPY;

EID: 85026258046     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2017.06.001     Document Type: Article

References (34)

1. Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 133 (2016), e38–e360.
2. Hankey, G.J., Norman, P.E., Eikelboom, J.W., Medical treatment of peripheral arterial disease. JAMA 295 (2006), 547–553.
3. Bhatt, D.L., Eagle, K.A., Ohman, E.M., et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 304 (2010), 1350–1357.
4. Turpie, A.G., Lassen, M.R., Eriksson, B.I., et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 105 (2011), 444–453.
5. Buller, H.R., Prins, M.H., Lensing, A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366 (2012), 1287–1297.
6. Bauersachs, R., Berkowitz, S.D., Brenner, B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363 (2010), 2499–2510.
7. Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
8. Mega, J.L., Braunwald, E., Wiviott, S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366 (2012), 9–19.
9. Steg, P.G., Huber, K., Andreotti, F., et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 32 (2011), 1854–1864.
10. Bhatt, D.L., Cryer, B.L., Contant, C.F., et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363 (2010), 1909–1917.
11. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [erratum in: 2002;324:141]. BMJ 324 (2002), 71–86.
12. Alexander, J.H., Hafley, G., Harrington, R.A., et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 294 (2005), 2446–2454.
13. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996), 1329–1339.
14. Bhatt, D.L., Fox, K.A., Hacke, W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006), 1706–1717.
15. Bhatt, D.L., Flather, M.D., Hacke, W., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49 (2007), 1982–1988.
16. Li, X., Zhou, G., Zhou, X., Zhou, S., The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. J Neurol Sci 332 (2013), 92–96.
17. Bonaca, M.P., Bhatt, D.L., Cohen, M., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372 (2015), 1791–1800.
18. Morrow, D.A., Braunwald, E., Bonaca, M.P., et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366 (2012), 1404–1413.
19. Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., Arnesen, H., Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347 (2002), 969–974.
20. van Es, R.F., Jonker, J.J., Verheugt, F.W., Deckers, J.W., Grobbee, D.E., Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 360 (2002), 109–113.
21. Anand, S.S., Yusuf, S., Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 41:4 suppl S (2003), 62S–69S.
22. Anand, S., Yusuf, S., Xie, C., et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357 (2007), 217–227.
23. Derry, S., Loke, Y.K., Risk of gastrointestinal hemorrhage with long term use of aspirin: meta-analysis. BMJ 321 (2000), 1183–1187.
24. Lanas, A., Wu, P., Medin, J., Mills, E.J., Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol 9 (2011), 762–768.
25. Lanas, Á., Carrera-Lasfuentes, P., Arguedas, Y., et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 13 (2015), 906–912.
26. Moayyedi, P., Leontiadis, G.I., The risks of PPI therapy. Nat Rev Gastroenterol Hepatol 9 (2012), 132–139.
27. Lazarus, B., Chen, Y., Wilson, F.P., et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 176 (2016), 238–246.
28. Gomm, W., von Holt, K., Thomé, F., et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol 73 (2016), 410–416.
29. Yusuf, S., Teo, K.K., Pogue, J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008), 1547–1559.
30. Brechenmacher, T., Xu, J., Dmitrienko, A., Tamhane, A.C., A mixture gatekeeping procedure based on the Hommel test for clinical trial applications. J Biopharm Stat 21 (2011), 748–767.
31. Vermeer, S.E., Longstreth, W.T. Jr., Koudstaal, P.J., Silent brain infarcts: a systematic review. Lancet Neurol 6 (2007), 611–619.
32. Bell, A.D., Roussin, A., Cartier, R., et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol 27:suppl A (2011), S1–S59.
33. Macle, L., Cairns, J., Leblanc, K., et al. 2016 Focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol 32 (2016), 1170–1185.
34. Rodriguez, F., Mahaffey, K.W., Management of patients with NSTE-ACS: a comparison of the recent AHA/ACC and ESC Guidelines. J Am Coll Cardiol 68 (2016), 313–321.